Here's the Cannabis Stock With the Most to Gain From Trump's Marijuana Rescheduling Push
President Trump showed support for looser regulations in the cannabis industry even before he was elected for his second term in office. For instance, he supported an initiative in his home state of Florida that aimed at making recreational use of marijuana legal for adults. And since he took office for his second term, there has been significant progress in the industry. Products containing marijuana approved by the U.S.
How this was made
The 30-second read
Why it matters
A move from Schedule I/II to Schedule III is presented as improving corporate profitability by allowing normal business expense deductions, which would be a structural margin benefit for qualifying operators like GTBIF.
Market read
This is a policy-expectations thesis tied to a hearing on further rescheduling, not a confirmed final regulatory outcome.
What to watch
Implementation details (scope of products, effective date, and any remaining restrictions) could materially change the net benefit; the article also does not address potential compliance costs or demand elasticity after rescheduling.
Background
The article claims FDA-approved marijuana products and state-regulated medical products are now treated as Schedule III, and describes a hearing considering further Schedule III moves.
Ticker impact
The article argues Green Thumb Industries could benefit if more cannabis products move into Schedule III, enabling normal expense deductions.
Moderate upside bias versus peers if rescheduling advances, but magnitude is uncertain because the article does not provide a specific decision outcome or timeline.
The text links Schedule III status to improved profit and margins via deductibility, and positions GTBIF as a stronger MSO with consistent profitability, but it does not confirm the hearing outcome or quantify the financial impact.
Market effects
If rescheduling progresses, it could improve after-tax economics for MSOs and distributors that currently face limits on deducting expenses for Schedule I/II products.
US-focused regulatory change, with effects concentrated in states where MSOs operate under limited-license regimes.
Limited direct global impact, but could influence international cannabis investment sentiment through US policy expectations.
Counterpoint
Even if Schedule III is discussed, the article provides no confirmation of final approval, so the trade may be premature and already priced into cannabis names.
Key entities
- companyGreen Thumb Industries
MSO highlighted as a potential biggest beneficiary from further cannabis rescheduling into Schedule III.
- regulatorU.S. Food and Drug Administration
Referenced as having already approved certain marijuana products that are now deemed Schedule III.
- governmentTrump administration
Referenced as supporting looser cannabis regulations and progress during the second term.
